Enveda collects another $150M for I&I drug, sprawling pipeline of preclinical assets

A Colorado biotech has gone from a $50,000 "pre, pre-seed" check from its founding CEO to $517 million in funding and unicorn status in five years. Enveda hit the $1 billion valuation milestone — a relative ...